Effectiveness of bupropion sustained release for smoking cessation in a health care setting - A randomized trial

被引:115
|
作者
Swan, GE
McAfee, T
Curry, SJ
Jack, LM
Javitz, H
Dacey, S
Bergman, K
机构
[1] SRI Int, Ctr Hlth Sci, Menlo Pk, CA 94025 USA
[2] Grp Hlth Cooperat Puget Sound, Ctr Hlth Promot, Seattle, WA 98121 USA
[3] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA
[4] Grp Hlth Cooperat Puget Sound, Ctr Pharm Adm, Seattle, WA 98101 USA
关键词
D O I
10.1001/archinte.163.19.2337
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The efficacy of bupropion hydrochloride sustained release (SR) (Zyban) for smoking cessation has been evaluated in clinical trials that included frequent in-person behavioral counseling, but not in actual practice settings. Objective: To determine the differential effectiveness of 2 doses of bupropion SR in combination with behavioral interventions of minimal to moderate intensity in an actual practice setting. Design: Open-label randomized trial, with 1 year of follow-up. Setting: A large health system (Group Health Cooperative) based in Seattle. Participants: Adult smokers (N=1524) interested in quitting smoking. Interventions: Participants were randomly assigned to receive 1 of 4 combinations of bupropion SR (150 or 300 mg) and behavioral counseling (minimal or moderate intensity). Main Outcome Measures: The primary outcome measure was self-reported point-prevalence 7-day nonsmoking status at 3 and 12 months following the target quit date. Secondary outcomes included adverse and abstinence effects reported since beginning treatment with bupropion SR. Results: At 3 months, a significantly higher rate of nonsmoking was observed among those receiving the larger bupropion SR dose (P=.005). At 12 months, moderate intensity counseling was associated significantly with a higher rate of nonsmoking (P=.001). At 3 months, the higher dose was associated with a significantly increased frequency of self-reported symptoms such as difficulty sleeping (P=.02), difficulty concentrating (P=.02), shakiness/tremor (P=.002), and gastrointestinal problems (P=.005)and a decreased frequency of reported desire to smoke (P=.001). Conclusions: In this actual practice setting, the combination of bupropion SR and minimal or moderate counseling was associated with 1-year quit rates of 23.6% to 33.2%. This suggests that existing health care systems can substantially decrease tobacco use rates among their enrollees if they provide these modest interventions.
引用
收藏
页码:2337 / 2344
页数:8
相关论文
共 50 条
  • [1] Bupropion sustained release and smoking cessation
    Goldstein, MG
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 : 66 - 72
  • [2] A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation
    Zernig, Gerald
    Wallner, Reinhild
    Grohs, Ursula
    Kriechbaum, Norbert
    Kemmler, Georg
    Saria, Alois
    [J]. ADDICTION, 2008, 103 (12) : 2024 - 2031
  • [3] Sustained-release bupropion for hospital-based smoking cessation: A randomized trial
    Simon, Joel A.
    Duncan, Carol
    Huggins, Joy
    Solkowitz, Sharon
    Carmody, Timothy P.
    [J]. NICOTINE & TOBACCO RESEARCH, 2009, 11 (06) : 663 - 669
  • [4] Sustained-release bupropion smoking cessation in African Americans - A randomized controlled trial
    Ahluwalia, JS
    Harris, KJ
    Catley, D
    Okuyemi, KS
    Mayo, MS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04): : 468 - 474
  • [5] Sustained-release bupropion for smoking cessation in the outpatient setting.
    Sayner-Flusche, A
    Strayer, SM
    Hodge, JA
    [J]. PHARMACOTHERAPY, 2002, 22 (10): : 1370 - 1370
  • [6] Sustained-release bupropion for smoking cessation
    Pasternak, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (09): : 619 - 620
  • [7] Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation
    David, Sean P.
    Brown, Richard A.
    Papandonatos, George D.
    Kahler, Christopher W.
    Lloyd-Richardson, Elizabeth E.
    Munafo, Marcus R.
    Shields, Peter G.
    Lerman, Caryn
    Strong, David
    McCaffery, Jeanne
    Niaura, Raymond
    [J]. NICOTINE & TOBACCO RESEARCH, 2007, 9 (08) : 821 - 833
  • [8] A controlled trial of nortriptyline or sustained-release bupropion for smoking cessation
    Haggstram, FM
    Chatkin, JM
    Sussenbach-Vaz, E
    Cesari, DH
    Fam, CF
    Fritscher, CC
    [J]. CHEST, 2004, 126 (04) : 714S - 714S
  • [9] Bupropion for smoking cessation - A randomized trial
    Simon, JA
    Duncan, C
    Carmody, TP
    Hudes, ES
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (16) : 1797 - 1803
  • [10] Assessment of the effectiveness of sustained release Bupropion and intensive physician advice in smoking cessation
    Singh, Pranav
    Kumar, Raj
    [J]. LUNG INDIA, 2010, 27 (01) : 11 - 18